CardiolRx Pharmaceutical Cannabidiol
In collaboration with Dalton Pharma Services, Cardiol is developing unique manufacturing expertise in the production of pharmaceutical cannabinoids in support of its nanotherapeutics program in heart failure.
With the de-scheduling of cannabinoids from the federal Controlled Drugs and Substances Act, Cardiol believes there is a significant opportunity to manufacture and commercialize pure pharmaceutical cannabidiol regulated by the federal Cannabis Act.
• FDA/Health Canada certified cGMP manufacturer
• Pharmaceutical cannabidiol
• Precise dosing
• >99.5% purity
• THC Free (less than 10 ppm)
New Frontier Data estimates that annual sales in Canada of medicinal cannabinoids in 2017 exceeded $600 million and forecasts sales to reach $1.2 billion in 2018. Cardiol believes that a pharmaceutical cannabidiol product, which will address a significant proportion of the total medicinal cannabinoid market, manufactured by a Health Canada regulated/FDA registered cGMP facility, will have key competitive advantages regarding traceability, dosimetry, consistency, and purity. Cardiol also believes this new class of cannabidiol-based products will provide the Company with a significant near-term revenue opportunity.